Format

Send to

Choose Destination
Int J Tuberc Lung Dis. 2015 Dec;19(12):1524-7. doi: 10.5588/ijtld.15.0274.

Beyond multidrug-resistant tuberculosis in Europe: a TBNET study.

Author information

1
Division of Clinical Infectious Diseases and German Center for Infection Research Tuberculosis Unit, Research Center Borstel, Borstel, Germany; Department of Medicine, University of Namibia School of Medicine, Windhoek, Namibia.
2
Department of Global Health, Academic Medical Center, University of Amsterdam and Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.
3
Hospital Universitari Vall d'Hebron, Barcelona, Spain; Investigació i Recerca en Atenció Primària Jordi Gol, Barcelona, Spain.
4
Heart of England Foundation Trust, Birmingham, UK.
5
Centro Hospitalar de Vila Nova Gaia/Espinho, Vila Nova Gaia, Portugal; EpiUnit, Institute of Public Health, Medical School Porto University, Porto, Portugal.
6
L Spallanzani National Institute for Infectious Diseases, Rome, Italy.
7
Heart of England Foundation Trust, Birmingham, UK; Queen Mary University, London, UK.
8
St Pieter University Medical Centre, Brussels, Belgium.
9
Marius-Nasta-Institut, Bucharest, Romania.
10
Azienda Ospedaliera di Valtellina e Valchiavenna E Morelli Hospital, Reference Hospital for MDR and HIV-TB, Sondalo, Italy; Department of Infection, Barts Health NHS Trust, London, UK.
11
National Institute for Health Development, Tallinn, Estonia.
12
Division of Clinical Infectious Diseases and German Center for Infection Research Tuberculosis Unit, Research Center Borstel, Borstel, Germany; Department of Medicine, University of Namibia School of Medicine, Windhoek, Namibia; Department of Medicine, Karolinska Institute, Stockholm, Sweden.

Abstract

The emergence of drug-resistant tuberculosis (TB) is a challenge to TB control in Europe. We evaluated second-line drug susceptibility testing in Mycobacterium tuberculosis isolates from patients with multidrug-resistant, pre-extensively drug-resistant (pre-XDR-TB) and XDR-TB at 23 TBNET sites in 16 European countries. Over 30% of bacilli from patients with pre-XDR-TB showed resistance to any fluoroquinolone and almost 70% to any second-line injectable drug. Respectively >90% and >80% of the XDR-TB strains tested showed phenotypic resistance to pyrazinamide and ethambutol. Resistance to prothionamide/ethionamide was high in bacilli from pre-XDR-TB patients (43%) and XDR-TB patients (49%).

PMID:
26614196
DOI:
10.5588/ijtld.15.0274
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Ingenta plc
Loading ...
Support Center